healthrx.com

SURMOUNT-4 Trial: A Plain-English Overview of What It Established

By
Updated
GLP-1 medication and metabolic health image for SURMOUNT-4 Trial: A Plain-English Overview of What It Established
Image: HealthRX.com clinical image

At a glance

Trial DetailValue
Trial nameSURMOUNT-4 (NCT04660643)
Enrolled (N)670 randomized (from 783 in lead-in)
InterventionTirzepatide (maximum tolerated dose: 10 mg or 15 mg weekly)
ComparatorMatching placebo (after 36-week open-label lead-in)
Total duration88 weeks (36-week lead-in + 52-week randomized phase)
Primary endpointPercent change in body weight from randomization (week 36) to week 88
Key resultTirzepatide group lost an additional 5.5%; placebo group regained 14.0%
Published2024, JAMA

The Question SURMOUNT-4 Was Built to Answer

Every prior obesity drug trial left the same loose thread: if you stop the medication, what happens? Earlier SURMOUNT trials (1 through 3) proved that tirzepatide produces large weight reductions in people with obesity. SURMOUNT-4 addressed the next clinical question directly. It asked whether those weight losses hold up once the drug is withdrawn, or whether continued treatment is necessary to maintain the benefit.

The design was a "randomized withdrawal" trial. Everyone received tirzepatide for 36 weeks first. Only those who tolerated it and lost weight were then randomly assigned to either keep going or switch to placebo. This structure isolated the specific effect of continuation versus discontinuation, removing the noise that comes from comparing people who never responded in the first place.

Who Was in the Trial

Participants were adults aged 18 or older with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). People with type 2 diabetes were excluded, keeping the study population consistent with the FDA-approved indication for Zepbound in obesity without diabetes.

Of 783 people who entered the open-label lead-in, 670 (85.6%) met the criteria for randomization at week 36. The most common reasons for not advancing were adverse events and voluntary withdrawal. The randomized group was roughly 70% female, with a mean age of 45 and a mean baseline BMI of 38 kg/m². By randomization, average weight loss during the lead-in was already 20.9%.

How the Trial Worked, Step by Step

Weeks 0 through 36 (open-label lead-in). All 783 participants received tirzepatide, titrated from 2.5 mg weekly up to the maximum tolerated dose of 10 mg or 15 mg. The titration schedule followed the same stepwise protocol used across the SURMOUNT program: 2.5 mg for four weeks, then increases every four weeks. Lifestyle counseling (a 500 kcal/day deficit and 150 minutes/week of physical activity) accompanied the drug throughout.

Week 36 (randomization). Those who had tolerated at least 10 mg weekly and completed the lead-in were randomized 1:1 to continue tirzepatide at their current dose or switch to matching placebo injections. Randomization was stratified by dose level (10 mg vs. 15 mg) and by the presence of prediabetes.

Weeks 36 through 88 (double-blind phase). For 52 weeks, neither participants nor investigators knew who was on drug versus placebo. Lifestyle counseling continued for both groups. Weight, waist circumference, cardiometabolic biomarkers, and adverse events were tracked at regular intervals.

The HealthRX.com Regain-vs-Retention Framework

To make the results concrete, we built a simple before-and-after comparison that tracks what happened to a hypothetical participant who weighed 240 lbs at trial entry.

TimepointTirzepatide ContinuationPlacebo (Switched Off Drug)
Week 0 (trial entry)240 lbs240 lbs
Week 36 (randomization), after ~20.9% loss~190 lbs~190 lbs
Week 88 (trial end)~179 lbs (additional 5.5% loss)~217 lbs (14.0% regain from week 36)
Net change from original baseline~25.3% total loss~9.6% total loss

The gap between the two groups at week 88 was 19.5 percentage points. Both groups started the randomized period at the same weight. By trial end, the placebo group had regained roughly two-thirds of the weight they initially lost, while the continuation group continued losing. That 19.5-point divergence was statistically significant (p < 0.001) and clinically meaningful by any obesity-medicine standard.

Detailed Results Beyond the Primary Endpoint

Waist circumference. The tirzepatide group lost an additional 4.3 cm from the waist during the randomized phase, while the placebo group gained 7.8 cm. The difference of 12.1 cm matters because waist circumference independently predicts cardiometabolic risk beyond what BMI captures.

Cardiometabolic markers. Systolic blood pressure, fasting insulin, and lipid panels all worsened in the placebo group after withdrawal while remaining stable or improving in the tirzepatide group. These shifts tracked closely with weight changes. Fasting glucose rose in the placebo group, consistent with the known relationship between adiposity rebound and insulin resistance.

Proportion reaching clinically meaningful thresholds. At week 88 to 97.3% of tirzepatide continuers maintained at least 80% of their lead-in weight loss. In the placebo group, that number dropped sharply. Roughly one in three placebo participants regained enough weight to fall below the 5% total-loss threshold that the AMA and Endocrine Society consider clinically significant.

Outcome at Week 88TirzepatidePlacebo
Mean % weight change from randomization−5.5%+14.0%
Maintained ≥5% loss from original baseline99.0%76.7%
Maintained ≥10% loss from original baseline96.8%52.4%
Maintained ≥20% loss from original baseline78.7%16.6%
Waist circumference change (cm)−4.3+7.8

Safety During the Randomized Phase

Adverse event rates were consistent with the broader tirzepatide safety profile. Gastrointestinal side effects (nausea, diarrhea, constipation) occurred more often in the tirzepatide group, though rates were lower than during the initial titration phase since participants had already been on stable doses for months.

Serious adverse events were reported in 3.0% of the tirzepatide group and 2.7% of the placebo group. No new safety signals appeared. One finding worth noting: the placebo group experienced a small uptick in musculoskeletal complaints during regain, possibly related to the mechanical stress of rapidly re-accumulating weight.

Discontinuation rates during the double-blind phase were low (roughly 5% in each arm), reflecting the pre-selection of tolerant responders during the lead-in.

Limitations the Authors Acknowledged

The randomized withdrawal design, while excellent for isolating the continuation question, introduces survivorship bias. The 15% of participants who dropped out during the lead-in (due to side effects or non-response) were excluded from the randomized phase. This means the trial's results apply specifically to people who tolerate and respond to tirzepatide, not to the broader population who might start it.

The 52-week randomized phase, while longer than many obesity trials, still leaves open the question of what happens over five or ten years. Weight regain in the placebo group appeared to be plateauing by week 88 in some subgroup analyses, but the trajectory was not fully settled.

The trial population was predominantly White (approximately 85%) and excluded people with type 2 diabetes, limiting generalizability. The SURMOUNT-2 trial covered the diabetes population separately, but a withdrawal study in that group has not been published.

Finally, the lead-in design means there was no true "start placebo from day one" arm. The trial cannot tell us whether a person who never took tirzepatide would have the same weight trajectory as someone who took it and stopped. The comparison is specifically between staying on versus coming off.

What SURMOUNT-4 Means for Clinical Practice

Three practical takeaways emerge from SURMOUNT-4.

First, obesity treatment with tirzepatide (and likely other GLP-1 receptor agonists) appears to require ongoing use. The 14% regain over 52 weeks after stopping is consistent with data from the STEP 1 extension trial with semaglutide, where participants regained roughly two-thirds of lost weight within a year of discontinuation. SURMOUNT-4 confirmed that this pattern is not unique to one molecule. It reflects the biology of obesity rather than a quirk of any single drug.

Second, the speed and magnitude of regain argue against "drug holidays." Some clinicians have considered intermittent dosing to reduce cost or side-effect burden. SURMOUNT-4 provides direct evidence against extended breaks. Weight regain began within weeks of switching to placebo and accumulated steadily.

Third, insurance and access conversations now have harder data. Payers who restrict GLP-1 prescriptions to short courses can no longer argue that the evidence supports limited treatment duration. SURMOUNT-4 demonstrated that stopping treatment reverses most of its benefit, supporting the 2024 AGA clinical practice guideline framing obesity pharmacotherapy as long-term.

Frequently asked questions

How much weight did people regain after stopping tirzepatide in SURMOUNT-4?

On average, participants who switched to placebo regained 14.0% of their body weight over 52 weeks (measured from the point of randomization at week 36). Since they had already lost about 20.9% during the lead-in, this left them with a net loss of roughly 9.6% from their original starting weight. That is less than half the total loss achieved by those who continued the drug.

Did anyone in the placebo group keep all their weight off?

A small minority did. About 16.6% of placebo participants maintained a 20% or greater loss from their original baseline at week 88. Most, though, experienced substantial regain. The results varied by individual, but the group-level trend was clearly toward significant weight recovery.

Is SURMOUNT-4 the reason tirzepatide is considered a long-term medication?

It is one of the strongest pieces of evidence, yes. The trial was specifically designed to test what happens when you stop. The clear regain pattern it documented, combined with parallel data from semaglutide trials, has led professional societies and the FDA to classify GLP-1 obesity medications as chronic therapies rather than short courses.

Were there safety concerns with staying on tirzepatide for 88 weeks?

No new safety signals appeared during the full 88-week treatment period. Gastrointestinal side effects were the most common complaint but occurred at lower rates during the maintenance phase than during initial dose titration. Serious adverse event rates were similar between the tirzepatide and placebo groups in the randomized phase.

How does SURMOUNT-4 compare to the STEP 1 extension with semaglutide?

Both trials showed similar patterns: roughly two-thirds of lost weight returned within a year of stopping the drug. SURMOUNT-4 used a randomized withdrawal design (everyone got drug first, then some switched to placebo), while STEP 1's extension was observational. The consistency across two different GLP-1 drugs strengthens the conclusion that this is a class-wide phenomenon tied to obesity biology.

Who was excluded from SURMOUNT-4?

People with type 2 diabetes, prior bariatric surgery, or a BMI below 27 were excluded. Those with a BMI of 27 to 29.9 needed at least one weight-related complication to qualify. The 15% who could not tolerate the drug or did not respond during the 36-week lead-in were also excluded from the randomized phase.

Does SURMOUNT-4 apply to people taking tirzepatide for diabetes?

Not directly. The trial excluded people with type 2 diabetes. SURMOUNT-2 studied tirzepatide in people with obesity and type 2 diabetes, but no randomized withdrawal trial has been published for that specific population. The biological principles are likely similar, but the data gap exists.

What dose of tirzepatide did participants take in SURMOUNT-4?

During the lead-in, participants were titrated to their maximum tolerated dose: either 10 mg or 15 mg weekly. The majority (roughly 80%) reached the 15 mg dose. They stayed on whichever dose they had reached for the entire randomized phase, whether they received active drug or matching placebo.

Can you do intermittent tirzepatide dosing based on SURMOUNT-4 results?

SURMOUNT-4 tested complete cessation, not dose reduction or intermittent use. The rapid and substantial regain observed after full withdrawal makes extended drug holidays look risky. Whether lower doses or less frequent injections could maintain weight loss is an open research question that SURMOUNT-4 did not address.

How long does it take to start regaining weight after stopping tirzepatide?

Weight regain in the placebo group became apparent within the first few weeks after randomization and accumulated steadily over the 52-week double-blind period. There was no prolonged "grace period." The trajectory suggests that the appetite and metabolic effects of tirzepatide begin fading soon after the last injection.

References

For More Info Visit HealthRx.com
Visit Now